Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3

Core Insights - Brown Advisory Mid-Cap Growth Strategy underperformed its benchmark, the Russell Midcap® Growth Index, which increased approximately 3% in the third quarter of 2025 [1] Company Overview - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) focuses on discovering and commercializing therapeutics based on ribonucleic acid interference [2][3] - As of December 18, 2025, Alnylam's stock closed at $396.04 per share, with a market capitalization of $52.322 billion [2] Performance Metrics - Alnylam Pharmaceuticals experienced a one-month return of -9.24% but gained 61.36% over the last 52 weeks [2] - The product revenue for Alnylam grew 103% year-over-year to $851 million in the third quarter of 2025 [3] Investment Sentiment - Alnylam Pharmaceuticals was held by 72 hedge fund portfolios at the end of the third quarter, an increase from 58 in the previous quarter [3] - Despite acknowledging Alnylam's potential, the company believes certain AI stocks offer greater upside potential and less downside risk [3]